Chronic kidney disease (CKD) is an alarming global health burden. Its complications lead to elevated disability and mortality rates. It is a long-term disease load to the healthcare system with a vast social cost equally in developed and developing countries. About 8 hundred million individuals all over the world suffer from some degree of CKD (1). All available therapeutic interventions for CKD are based on preventing the deterioration of the condition and keeping the blood glucose and blood pressure normal (2). Consequently, new treatment approval is extremely needed either for stoppage the progression of the disease or improvement of the kidney function (3). The Adenine -induced model of CKD is a very helpful and commonly used approach helping to understand the physiological, biochemical, and histopathological backgrounds of the disease, testing the different useful therapeutic approaches (4).